Steminent Biotherapeutics, Inc.

Steminent Biotherapeutics, Inc. is a biotechnology company specializing in the research and development of innovative cellular therapeutics, particularly focusing on stem cell-based treatments. Its primary mission is to address diseases with unmet or under-served medical needs through the advancement of allogeneic mesenchymal stem cell technology platforms. The company’s flagship product, Stemchymal, targets neurodegenerative disorders including spinocerebellar ataxia and Huntington’s disease, as well as indications such as acute ischemic stroke, inflammatory conditions, and osteoarthritis of the knee. Steminent’s diverse product pipeline comprises both pre-clinical and clinical stage programs and is shaped by ongoing efforts to expand the therapeutic applications of stem cell technologies. Founded in 2009 and headquartered in Taipei, Taiwan, Steminent Biotherapeutics plays a significant role in the healthcare sector, contributing to medical research and potential therapies that impact neurology, orthopedics, and systemic inflammatory diseases. The company operates internationally, with additional offices in Shanghai and San Diego, underscoring its role in the global biotechnology landscape.